Tough Decision Making in Pembrolizumab-Associated Acute Interstitial Nephritis: A Case Report
Pembrolizumab is an immune checkpoint inhibitor used as a cancer therapy. The incidence of immune related adverse events in patients receiving immune checkpoint inhibitors can be as high as 59%-85%. Renal adverse effects are uncommon, but the incidence of kidney toxicity related to pembrolizumab is...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
Publicações Ciência e Vida,
2023-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|